Brain Biotech Ag · XETR:BNN
Brain Biotech — Investor Day (February 2023)
14 slides from Brain Biotech's investor day presentation, Feb 27, 2023
Slide 1: BRAIN Biotech AG Capital Markets Day 2023
BRAIN Biotech AG Creating a #BiobasedFuture Capital Markets Day 2023 Zwingenberg, February 27, 2023 Since 2021 we have been committed to the UN Global Compact corporate responsibility initiative and its principles in the areas of human rights, labor, the environment and anti-corruption. Creating a #
Slide 2: Beyond Industrial Biotech: Akribion Genomics
Capital Markets Day 2023 Creating a #BiobasedFuture Beyond Industrial Biotech: Akribion Genomics Lukas Linnig, Co-CEO & Dr. Dirk Sombroek, Head of Strategic Partnerships Creating a #BiobasedFuture © BRAIN Biotech AG Zwingenberg Germany www.brain-biotech.com +49 (0) 6251-9331-0 72
Slide 3: Akribion Genomics – Vision and mission
Akribion Genomics – Vision and mission democratizing access to Genome Editing tools enabling novel opportunities to edit the living for the better We have a clear vision: To become a leading player in the genome editing landscape… … by enabling others with the tools and technology (<picks & shovels=
Slide 4: Akribion Genomics – Management Team
Akribion Genomics – Management Team from the start with a strong senior management team Akribion Executive Board Akribion Senior Management Team Dr. Michael Krohn Lukas Linnig Dr. Paul Scholz Dr. Dirk Sombroek Dr. Oliver Grünvogel Co-Founder & CEO Co-Founder & CEO Head of R&D Head Strat. Partnership
Slide 5: Akribion Genomics – Unique Technology Platform
Akribion Genomics – Unique Technology Platform two distinct proprietary CRISPR nuclease families that can go beyond the limitations of current genome editing tools G-dase M G-dase E Double Strand Break Transcription G-dase E G-dase M Genome Vital Cell mRNA or ncRNA Guided Gene Toxicity Knock-Out • (
Slide 6: Akribion Genomics – Several USPs
Akribion Genomics – Several USPs technology advantage in G-dase E, supported by independent IP and simpler access How Akribion can use Market situation and how Akribion can address this this to win • Strong market concentration of IP developers (Cas9, CpfI) and reach-through of Independence Propriet
Slide 7: Akribion Genomics – Markets and segments
Akribion Genomics – Markets and segments four focus segments with high growth and a combined market potential of over 17 Bn $ by 2031 First Industries to address Key applications for G-Dase E & G-dase M Revenue Generation model Total Market size ($m)* • Depletion/Killing of cancerous cells in-vivo (
Slide 8: G-dase E's unique Mode of Action
Akribion Genomics – G-dase E9s unique Mode of Action G-dase E offers a unique Mode of Action with a targeted cell-killing mechanism G-dase E active in human cells Specific cell depletion in vitro based on a specific RNA marker Non-targeted cells survive the addition of G-dase E while being in
Slide 9: Unique Therapeutics Application (1/2)
Focus Therapeutics Akribion Genomics – Unique Therapeutics Application (1/2) G-dase-derived pharmaceuticals can be applied in oncology for the depletion/killing of cancerous cells in-vivo • Specific based on RNA biomarkers • Various sub-indications targetable Core Capabilities Core No capabilities c
Slide 10: Unique Therapeutics Application (2/2)
Focus Therapeutics Akribion Genomics – Unique Therapeutics Application (2/2) combination of G-dase E and M can be applied in cell-based therapies, to increase the editing efficiency in patient- derived cells ex-vivo G-dase M • T-cell /NK therapies for oncology treatment (or other genome editing tool
Slide 11: Therapeutics Strategy
Focus Therapeutics Akribion Genomics – Therapeutics Strategy increasing levels of <proof-of-concept= will allow us to showcase the value of our technology for therapeutic applications Addressing Tx-Market Proof of Concept Levels • Level 0: evaluate & identify 1st Level PoC 2nd Level PoC 3rd Level Po
Slide 12: Business Development Roadmap
Akribion Genomics – Business Development Roadmap core priorities will evolve in three distinct phases, in turn shifting the focus of our business development activities Phase Phase 1: Awareness and Phase 2: Outlicense and Phase 3: Maximize value proof-of-concept grow pipeline generation 2023-2024 20
Slide 13: Relation to BRAIN Biotech AG
Akribion Genomics – Relation to BRAIN Biotech AG BRAIN will focus on applying CRISPR in White Biotech applications, while Akribion focuses on developing and commercializing the technology platform with a focus on therapeutics Project A undisclosed Project B TMS Biotech AG We CRISPR for you! Project
Slide 14: A Very Exciting Business Opportunity
Akribion Genomics – A Very Exciting Business Opportunity Unique technology platform with the potential to create a new class of treatment for cancer Edit the living for the better! Huge market potential in therapeutics with highly attractive alternative use cases Strong partners are successivel